The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor

被引：1

作者：

Kaur, Jatinder ^{[1
]}

Bhardwaj, Atul ^{[1
]}

Melancon, Bruce J. ^{[1
]}

Blagg, Brian S. J. ^{[1
]}

机构：

[1] Univ Notre Dame, Dept Chem & Biochem, Warren Family Res Ctr Drug Discovery & Dev, Notre Dame, IN 46556 USA

来源：

SYNTHETIC COMMUNICATIONS | 2019年 / 49卷 / 11期

基金：

美国国家卫生研究院;

关键词：

AT13387; cost-effective synthetic route; Hsp90; iso-indoline; proteostasis; MOLECULAR CHAPERONES; DISCOVERY; COMPLEX;

D O I：

10.1080/00397911.2019.1602654

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

AT13387 is an orally bioavailable clinical candidate developed to inhibit heat shock protein 90 (Hsp90). This article describes a modified synthetic route for the multi-gram production of AT13387 in 46% overall yield. The modified synthetic route is short, avoids stringent reaction conditions and difficult purifications, which led to an increase in overall yield.

引用

页码：1436 / 1443

页数：8

共 50 条

[21] The HSP90 inhibitor, AT13387, combined with erlotinib improves response in EGFR-driven xenograft models of NSCLC
Smyth, Tomoko
Lewis, Jon
Hearn, Keisha
Thompson, Neil
Lyons, John
Wallis, Nicola G.
[J]. CANCER RESEARCH, 2014, 74 (19)
[22] A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation
Chan, King Chi
Ting, Choi Man
Chan, Pui Shan
Lo, Ming Chu
Lo, Kwok Wai
Curry, Jayne E.
Smyth, Tomoko
Lee, Anne Wing Mui
Ng, Wai Tong
Tsao, George Sai Wah
Wong, Ricky Ngok Shun
Lung, Maria Li
Mak, Nai Ki
[J]. MOLECULAR CANCER, 2013, 12
[23] Design and validation of pharmacodynamic assays to measure the activity of the HSP90 inhibitor, AT13387 in surrogate tissue and tumor in a phase I study
Lyons, J.
Squires, M.
Lock, V.
Graham, B.
Smyth, T.
Ong, E.
Mahadevan, D.
Kwak, E.
Shapiro, G.
[J]. EJC SUPPLEMENTS, 2010, 8 (07): : 187 - 187
[24] A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation
King Chi Chan
Choi Man Ting
Pui Shan Chan
Ming Chu Lo
Kwok Wai Lo
Jayne E Curry
Tomoko Smyth
Anne Wing Mui Lee
Wai Tong Ng
George Sai Wah Tsao
Ricky Ngok Shun Wong
Maria Li Lung
Nai Ki Mak
[J]. Molecular Cancer, 12
[25] Comparison of long-term pharmacodynamic actions of the synthetic small molecule HSP90 inhibitor AT13387 in multiple xenograft models
Lyons, John
Curry, Jayne
Smyth, Tomoko
Harada, Isobel
Fazal, Lynsey
Reule, Matthias
Graham, Brent
Thompson, Neil
[J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
[26] THE HSP90 INHIBITOR, AT13387, DISPLAYS SINGLE AGENT ACTIVITY IN ERLOTINIB-SENSITIVE AND -RESISTANT MODELS OF EGFR-ACTIVATED NSCLC
Hearn, Keisha
Smyth, Tomoko
Lewis, Jon
Martins, Vanessa
Thompson, Neil
Azab, Mohammad
Lyons, John
Wallis, Nicola G.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S464 - S464
[27] Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer
Williams, Nicole O.
Quiroga, Dionisia
Johnson, Courtney
Brufsky, Adam
Chambers, Mara
Bhattacharya, Saveri
Patterson, Maria
Sardesai, Sagar D.
Stover, Daniel
Lustberg, Maryam
Noonan, Anne M.
Cherian, Mathew
Bystry, Darlene M.
Hill, Kasey L.
Chen, Min
Phelps, Mitch A.
Grever, Michael
Stephens, Julie A.
Ramaswamy, Bhuvaneswari
Carson III, William E.
Wesolowski, Robert
[J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[28] Combining the HSP90 Inhibitor, AT13387, with Vemurafenib Delays the Emergence of Resistance in a Preclinical Model of BRAFV600E Mutant Melanoma
Smyth, T.
Lewis, J.
Thompson, N.
Lyons, J.
Azab, M.
Wallis, N.
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 58 - 58
[29] Total synthesis of the Hsp90 inhibitor geldanamycin
Oin, Hua-Li
Panek, James S.
[J]. ORGANIC LETTERS, 2008, 10 (12) : 2477 - 2479
[30] Concise synthesis of pochonin A, an HSP90 inhibitor
Moulin, E
Barluenga, S
Winssinger, N
[J]. ORGANIC LETTERS, 2005, 7 (25) : 5637 - 5639

← 1 2 3 4 5 →